Nav: Home

A new chemogenetic toolset

March 14, 2019

Inching closer to extending the approach to humans, researchers seeking to improve a promising strategy for noninvasively controlling cellular activity have reported the design of engineered ion-channels that can be activated by low doses of the FDA-approved anti-smoking drug varenicline. They tested their approach - one based on chemogenetics - in live mice and a monkey. Chemogenetics enables non-invasive chemical control over cell populations in behaving animals; it works through processes involving engineering of macromolecules to interact with previously unrecognized small molecules. To date, efforts to use chemogenetics in live animals have suffered from several setbacks, including lacking effective activating molecules. What's more, existing approaches are not compatible with human therapies; ideally, they should involve receptors potently activated by existing clinically approved drugs. Here, Christopher Magnus and colleagues sought to improve on chemogenetic systems. They developed a new ion channel-based platform for studying cell activation and silencing by chemical compounds. They then examined 44 clinically used drugs to see which best activated many of the mutant channels in their platform. The anti-smoking drug, varenicline, was a strong performer, they say, even at very small concentrations. The researchers modified varenicline to improve its potency, and then tested it as a neuron silencer in neuronal cells, where it was effective. They next administered it in the brains of live mice and in a live rhesus monkey, where Magnus and colleagues reported it affected neurons so as to induce behavioral changes. The work is a proof of principle that the authors' compound/ion channel combination approach can both silence and activate neurons and have a behavioral impact. The authors say their platform will enable translational studies in humans.

American Association for the Advancement of Science

Related Varenicline Articles:

A new chemogenetic toolset
Inching closer to extending the approach to humans, researchers seeking to improve a promising strategy for noninvasively controlling cellular activity have reported the design of engineered ion-channels that can be activated by low doses of the FDA-approved anti-smoking drug varenicline.
Using an anti-smoking drug to control neurons
A potent chemogenetic system pairs an anti-smoking drug with specially engineered proteins to change neuron activity.
Study identifies predictors of psychiatric events during drug-assisted smoking cessation
Researchers at UC San Diego School of Medicine have identified a clear group of characteristics that predict heightened risk for experiencing increased anxiety or worsening of mood that interferes with daily activities when using a smoking cessation drug.
Are e-cigarettes safer and more effective than other treatments for quitting smoking?
While not an FDA-approved treatment, e-cigarettes are used as, or more often by smokers to help them quit smoking, versus FDA-approved treatments for smoking cessation.
Cancer patients can quit smoking through lengthened medication time, counseling support
More than 50 percent of cancer patients still smoke after being diagnosed, yet quitting smoking can significantly improve the effectiveness of cancer treatment.
Common anti-smoking treatment makes no difference in shisha tobacco addiction
Researchers at the University of York has shown that a drug commonly used to help smokers overcome addiction to cigarettes does not have the same effect in shisha smokers.
37 percent of smokers fully switch to vaping blu after 90 days -- real-world study
Study of adult smokers in Glasgow given blu PRO vaping device and liquids sees more than a third completely switch to vaping with significant reductions in average smoking frequency for the other participants.
No clear evidence that nicotine 'preloading' helps smokers to quit
There is insufficient evidence to show that using nicotine patches for four weeks before a quit attempt (known as 'preloading') improves long-term smoking abstinence, finds a trial published by The BMJ this week.
Smoking in patients with heart attack reduced with varenicline
In patients who have had a heart attack, the drug varenicline significantly reduced smoking during the following year, found a randomized controlled trial published in CMAJ (Canadian Medical Association Journal).
Benefits of smoking cessation medications diminish over time
A new Tel Aviv University study published in Addiction finds that only eight out of 100 smokers who take smoking cessation medications will have benefited from taking smoking medications after one year's time.

Related Varenicline Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...